BOSTON, Feb. 20, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (NASDAQ:TORC), a clinical-stage biopharmaceutical company
focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases, today announced
that Joan Mannick, M.D., Chief Medical Officer, will present a company overview at the 2018 RBC Capital Markets Global Healthcare
Conference on Thursday, February 22, 2018 at 2:05 p.m. ET in New York.
A live webcast of the presentation can be accessed on the Investors section of resTORbio’s website at http://ir.restorbio.com/investors.
About resTORbio
resTORbio, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel
therapeutics for the treatment of aging-related diseases. resTORbio’s lead program focuses on selective inhibition of the target of
rapamycin complex 1 (TORC1) pathway to treat aging-related diseases with an initial focus on diseases caused by immunosenescence,
the decline in immune function that occurs during aging.
Contacts:
Beth DelGiacco
Stern Investor Relations, Inc.
212-362-1200
beth@sternir.com
Michael Lampe
Scient PR
484-575-5040
michael@scientpr.com
